Douglas L Nguyen1, Emily T Nguyen, Matthew L Bechtold. 1. Department of Medicine, UC Irvine School of Medicine, University of California - Irvine, 333 City Blvd. West, Suite 400, Orange, CA, 92868, USA, douglaln@uci.edu.
Abstract
BACKGROUND: Several studies have evaluated the effect of immunosuppressive therapy for the treatment of inflammatory bowel disease (IBD) on response to routine vaccinations. The overall effect of specific classes of medications (i.e., immunomodulator vs. biologics) on vaccine response remains undefined. The aim of this study was to determine the effect of each class of immunosuppressive therapy in IBD patients on response to routine vaccinations. METHODS: A comprehensive search of PubMed/MEDLINE, Scopus, CINAHL, and Cochrane databases was performed (December 2014). All studies on adults comparing vaccine response among IBD patients on immunosuppression with non-immunosuppressed patients were included. Meta-analysis was performed using the Mantel-Haenszel (fixed effects) model with odds ratio (OR) to assess for adequate vaccine response. RESULTS: In the pooled analysis of nine studies (N = 1474), we found that there was nearly a 60 % lower chance of achieving adequate seroprotection in the group that received immunosuppressive therapy compared to the group that was not on any immunosuppressive therapies (OR 0.41 95 % CI 0.30, 0.55, p < 0.001). Specifically, we also demonstrated that patients on immunomodulator monotherapy had a twofold higher probability of achieving adequate immune response to vaccination, compared to patients on anti-tumor necrosis factor (anti-TNF) monotherapy (OR 1.92 95 % CI 1.30, 2.84). CONCLUSION: In conclusion, IBD patients on immunosuppressive therapy have a significantly lower response to routine vaccinations. The greatest effect is seen among patients on anti-TNF and combination immunosuppressive therapy. Routine monitoring of vaccine titers post-vaccination is important to ensure that adequate immunologic response has been achieved among IBD patients.
BACKGROUND: Several studies have evaluated the effect of immunosuppressive therapy for the treatment of inflammatory bowel disease (IBD) on response to routine vaccinations. The overall effect of specific classes of medications (i.e., immunomodulator vs. biologics) on vaccine response remains undefined. The aim of this study was to determine the effect of each class of immunosuppressive therapy in IBDpatients on response to routine vaccinations. METHODS: A comprehensive search of PubMed/MEDLINE, Scopus, CINAHL, and Cochrane databases was performed (December 2014). All studies on adults comparing vaccine response among IBDpatients on immunosuppression with non-immunosuppressed patients were included. Meta-analysis was performed using the Mantel-Haenszel (fixed effects) model with odds ratio (OR) to assess for adequate vaccine response. RESULTS: In the pooled analysis of nine studies (N = 1474), we found that there was nearly a 60 % lower chance of achieving adequate seroprotection in the group that received immunosuppressive therapy compared to the group that was not on any immunosuppressive therapies (OR 0.41 95 % CI 0.30, 0.55, p < 0.001). Specifically, we also demonstrated that patients on immunomodulator monotherapy had a twofold higher probability of achieving adequate immune response to vaccination, compared to patients on anti-tumornecrosis factor (anti-TNF) monotherapy (OR 1.92 95 % CI 1.30, 2.84). CONCLUSION: In conclusion, IBDpatients on immunosuppressive therapy have a significantly lower response to routine vaccinations. The greatest effect is seen among patients on anti-TNF and combination immunosuppressive therapy. Routine monitoring of vaccine titers post-vaccination is important to ensure that adequate immunologic response has been achieved among IBDpatients.
Authors: Susan Armijo-Olivo; Carla R Stiles; Neil A Hagen; Patricia D Biondo; Greta G Cummings Journal: J Eval Clin Pract Date: 2010-08-04 Impact factor: 2.431
Authors: Tamás Molnár; Klaudia Farkas; István Jankovics; Márta Melles; Ferenc Nagy; Zoltán Szepes; Tibor Wittmann Journal: Am J Gastroenterol Date: 2011-02 Impact factor: 10.864
Authors: Anita Bálint; Klaudia Farkas; Pallagi-Kunstár Éva; Gabriella Terhes; Edit Urbán; Mónika Szucs; Tibor Nyári; Zsuzsanna Bata; Ferenc Nagy; Zoltán Szepes; Pál Miheller; Katalin Lorinczy; Péter László Lakatos; Barbara Lovász; Szamosi Tamás; Andrea Kulcsár; Anna Berényi; Dalma Törocsik; Tímea Daróczi; Zoltán Saródi; Tibor Wittmann; Tamás Molnár Journal: Scand J Gastroenterol Date: 2014-11-11 Impact factor: 2.423
Authors: G Andrisani; D Frasca; M Romero; A Armuzzi; C Felice; M Marzo; D Pugliese; A Papa; G Mocci; I De Vitis; G L Rapaccini; B B Blomberg; L Guidi Journal: J Crohns Colitis Date: 2012-06-05 Impact factor: 9.071
Authors: James A Church; Edward Pk Parker; Margaret N Kosek; Gagandeep Kang; Nicholas C Grassly; Paul Kelly; Andrew J Prendergast Journal: Future Microbiol Date: 2018-06-21 Impact factor: 3.165
Authors: Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade Journal: J Cutan Med Surg Date: 2018-11-21 Impact factor: 2.092